Selective cellular uptake and retention of SN 28049, a new DNA-binding topoisomerase II-directed antitumor agent

详细信息    查看全文

• 作者：Ying Yi Chen (1)
  Pradeep B. Lukka (1) (2)
  Wayne R. Joseph (1)
  Graeme J. Finlay (1)
  James W. Paxton (2)
  Mark J. McKeage (1) (2)
  Bruce C. Baguley (1)
  
• 关键词：Benzonaphthyridine ; Topoisomerase poison ; Multidrug resistance ; Cytoplasmic vesicles
• 刊名：Cancer Chemotherapy and Pharmacology
• 出版年：2014
• 出版时间：July 2014
• 年：2014
• 卷：74
• 期：1
• 页码：25-35
• 全文大小：1,899 KB
• 参考文献：1. Smalley KS, Flaherty KT (2009) Integrating BRAF/MEK inhibitors into combination therapy for melanoma. Br J Cancer 100:431-35 CrossRef
  2. Brown JM, Wilson WR (2004) Exploiting tumor hypoxia in cancer treatment. Nat Rev Cancer 4:437-47 CrossRef
  3. Deady LW, Rodemann T, Zhuang L, Baguley BC, Denny WA (2003) Synthesis and cytotoxic activity of carboxamide derivatives of benzo[b][1,6]naphthyridines. J Med Chem 46:1049-054 CrossRef
  4. Deady LW, Rogers ML, Zhuang L, Baguley BC, Denny WA (2005) Synthesis and cytotoxic activity of carboxamide derivatives of benzo[b][1,6]naphthyridin-(5H)ones. Bioorg Med Chem 13:1341-355 CrossRef
  5. Bridewell DJ, Porter AC, Finlay GJ, Baguley BC (2008) The role of topoisomerases and RNA transcription in the action of the antitumour benzonaphthyridine derivative SN 28049. Cancer Chemother Pharmacol 62:753-62 CrossRef
  6. Drummond CJ, Finlay GJ, Broome L, Marshall ES, Richardson E, Baguley BC (2011) Action of SN 28049, a new DNA binding topoisomerase II-directed antitumour drug: comparison with doxorubicin and etoposide. Invest New Drugs 29:1102-110 CrossRef
  7. Chen YY, Finlay GJ, Kirker JA, Marshall ES, Richardson E, Baguley BC (2011) In vivo and in vitro assessment of the action of SN 28049, a benzonaphthyridine derivative targeting topoisomerase II, on the murine Colon 38 carcinoma. Invest New Drugs 29:1504-510 CrossRef
  8. Muggia FM, Green MD (1991) New anthracycline antitumor antibiotics. Crit Rev Oncol Hematol 11:43-4 CrossRef
  9. Nelson EM, Tewey K, Liu LF (1984) Mechanism of antitumor drug action: poisoning of mammalian DNA topoisomerase II on DNA by 4 / -/em>-(9-acridinylamino)-methanesulfon-m-anisidide. Proc Natl Acad Sci USA 81:1361-365 CrossRef
  10. Tewey KM, Rowe TC, Yang L, Halligan BD, Liu LF (1984) Adriamycin-induced DNA damage mediated by mammalian DNA topoisomerase II. Science (New York, NY) 226:466-468
  11. Atwell GJ, Rewcastle GW, Baguley BC, Denny WA (1987) Potential antitumor agents. 50. In vivo solid-tumor activity of derivatives of N-[2-(dimethylamino)ethyl]acridine-4-carboxamide. J Med Chem 30:664-69 CrossRef
  12. Finlay GJ, Riou JF, Baguley BC (1996) From amsacrine to DACA (N-[2-(dimethylamino)ethyl]acridine-4-carboxamide): selectivity for topoisomerases I and II among acridine derivatives. Eur J Cancer 32A:708-14 CrossRef
  13. Davey RA, Su GM, Hargrave RM, Harvie RM, Baguley BC, Davey MW (1997) The potential of N-[2-(dimethylamino)ethyl]acridine-4-carboxamide to circumvent three multidrug-resistance phenotypes in vitro. Cancer Chemother Pharmacol 39:424-30 CrossRef
  14. McCrystal MR, Evans BD, Harvey VJ, Thompson PI, Porter DJ, Baguley BC (1999) Phase I study of the cytotoxic agent N-[2-(dimethylamino)ethyl]acridine-4-carboxamide. Cancer Chemother Pharmacol 44:39-4 CrossRef
  15. Twelves C, Campone M, Coudert B, Van den BM, de Jonge M, Dittrich C, Rampling R, Sorio R, Lacombe D, de Balincourt C, Fumoleau P (2002) Phase II study of XR5000 (DACA) administered as a 120-h infusion in patients with recurrent glioblastoma multiforme. Ann Oncol 13:777-80 CrossRef
  16. Baguley BC (2012) The development of new DNA intercalating anti-cancer drugs. In: Watanabe HS (ed) Horizons in cancer research, vol 48. Nova Publishers, pp 47-5. ISBN: 978-1-62100-524-7
  17. Baguley BC, Zhuang L, Marshall E (1995) Experimental solid tumour activity of N-[2-(dimethylamino)ethyl]- acridine-4-carboxamide. Cancer Chemother Pharmacol 36:244-48 CrossRef
  18. Lukka PB, Paxton JW, Kestell P, Baguley BC (2012) Comparison of a homologous series of benzonaphthyridine anti-cancer agents in mice: divergence between tumour and plasma pharmacokinetics. Cancer Chemother Pharmacol 70:151-60 CrossRef
  19. Lukka PB, Chen YY, Finlay GJ, Joseph WR, Richardson E, Paxton JW, Baguley BC (2013) Tumour tissue selectivity in the uptake of SN 28049, a new topoisomerase II-directed anticancer agent. Cancer Chemother Pharmacol 72:1013-022 CrossRef
  20. Stones CJ, Kim JE, Joseph WR, Leung E, Marshall ES, Finlay GJ, Shelling AN, Baguley BC (2013) Comparison of responses of human melanoma cell lines to MEK and BRAF inhibitors. Front Genet 4:66-1 CrossRef
  21. Griswold DP, Corbett TH (1975) A colon tumor model for anticancer agent evaluation. Cancer 36:2441-444 CrossRef
  22. Goldin A, Venditti JM, MacDonald JS, Muggia FM, Henney JE, DeVita VT Jr (1981) Current results of the screening program at the Division of Cancer Treatment, National Cancer Institute. Eur J Cancer 17:129-42 CrossRef
  23. Wilkoff L, Dulmadge E, Chopra D (1980) Viability of cultured Lewis lung cell populations exposed to beta-retinoic acid. Exp Biol Med 163:233-36
  24. Marshall ES, Finlay GJ, Matthews JH, Shaw JH, Nixon J, Baguley BC (1992) Microculture-based chemosensitivity testing: a feasibility study comparing freshly explanted human melanoma cells with human melanoma cell lines. J Natl Cancer Inst 84:340-45 CrossRef
  25. Marshall ES, Holdaway KM, Shaw JH, Finlay GJ, Matthews JH, Baguley BC (1993) Anticancer drug sensitivity profiles of new and established melanoma cell lines. Oncol Res 5:301-09
  26. Kim JE, Stones C, Joseph WR, Leung E, Finlay GJ, Shelling AN, Phillips WA, Shepherd PR, Baguley BC (2012) Comparison of growth factor signalling pathway utilisation in cultured normal melanocytes and melanoma cell lines. BMC Cancer 12:141 CrossRef
  27. Beck WT, Mueller TJ, Tanzer LR (1979) Altered surface membrane glycoproteins in Vinca alkaloid-resistant human leukemic lymphoblasts. Cancer Res 39:2070-076
  28. Davey RA, Longhurst TJ, Davey MW, Belov L, Harvie RM, Hancox D, Wheeler H (1995) Drug resistance mechanisms and MRP expression in response to epirubicin treatment in a human leukaemia cell line. Leuk Res 19:275-82 CrossRef
  29. Lukka PB, Paxton JW, Atwell GJ, Kestell P, Baguley BC (2012) A rapid LC-MS/MS method for the quantitation of a series of benzonaphthyridine derivatives: application to in vivo pharmacokinetic and lipophilicity studies in drug development. J Pharm Biomed Anal 63:9-6 CrossRef
  30. Haldane A, Finlay GJ, Hay MP, Denny WA, Baguley BC (1999) Cellular uptake of N-[2-(dimethylamino)ethyl]acridine-4-carboxamide (DACA). Anticancer Drug Des 14:275-80
  31. Kazmi F, Hensley T, Pope C, Funk RS, Loewen GJ, Buckley DB, Parkinson A (2013) Lysosomal sequestration (trapping) of lipophilic amine (cationic amphiphilic) drugs in immortalized human hepatocytes (Fa2?N-4 cells). Drug Metab Dispos 41:897-05 CrossRef
  32. Lemieux B, Percival MD, Falgueyret JP (2004) Quantitation of the lysosomotropic character of cationic amphiphilic drugs using the fluorescent basic amine Red DND-99. Anal Biochem 327:247-51 CrossRef
  33. Larsen AK, Escargueil AE, Skladanowski A (2000) Resistance mechanisms associated with altered intracellular distribution of anticancer agents. Pharmacol Ther 85:217-29 CrossRef
  34. Wright PK (2008) Targeting vesicle trafficking: an important approach to cancer chemotherapy. Recent Pat Anticancer Drug Discov 3:137-47 CrossRef
  35. Yamagishi T, Sahni S, Sharp DM, Arvind A, Jansson PJ, Richardson DR (2013) P-glycoprotein mediates drug resistance via a novel mechanism involving lysosomal sequestration. J Biol Chem 288:31761-1771 CrossRef
  36. Lukka PB, Paxton JW, Kestell P, Baguley BC (2010) Pharmacokinetics and distribution of SN 28049, a novel DNA binding anticancer agent, in mice. Cancer Chemother Pharmacol 65:1145-152 CrossRef
  37. Harris JR, Timberlake N, Henson P, Schimke P, Belli JA (1979) Adriamycin uptake in V79 and Adriamycin resistant Chinese hamster cells. Int J Radiat Oncol Biol Phys 5:1235-239 CrossRef
  38. Baguley BC (2010) Multidrug resistance in cancer. Methods Mol Biol 596:1-4 CrossRef
  
• 作者单位：Ying Yi Chen (1)
  Pradeep B. Lukka (1) (2)
  Wayne R. Joseph (1)
  Graeme J. Finlay (1)
  James W. Paxton (2)
  Mark J. McKeage (1) (2)
  Bruce C. Baguley (1)
  
  1. Auckland Cancer Society Research Centre, Faculty of Medical and Health Sciences, University of Auckland, Private Bag 92019, Auckland, 1142, New Zealand
  2. Department of Pharmacology and Clinical Pharmacology, University of Auckland, Private Bag 92019, Auckland, New Zealand
  
• ISSN：1432-0843

文摘

Purpose SN 28049 is a new DNA-binding topoisomerase II poison identified by its curative activity against the murine colon 38 carcinoma. Previous studies showed activity to be associated with selective drug accumulation and retention in tumour tissue. Retention varied widely among different tumours and was related to antitumour activity. We determined whether differences in the uptake and retention of SN 28049 could be observed in vitro. Methods The Co38P and LLTC lines were derived from the murine colon 38 carcinoma and Lewis lung carcinoma (3LL), respectively. The NZM4, NZM10 and NZM52 human melanoma lines, as well as the CCRF/CEM, CEM/VLB100 and CEM/E1000 human leukaemia lines were also utilised. Cell-associated drug was measured by liquid chromatography–mass spectrometry, laser-scanning confocal microscopy and fluorescence microscopy. Data for SN 28049 were compared for four SN 28049 analogues, for the structurally related drug N-[2-(dimethylamino)-ethyl]acridine-4-carboxamide (DACA) and for doxorubicin. Results Cellular uptake of SN 28049 was rapid and associated with increased fluorescence in cytoplasmic vesicles or bodies. SN 28049 uptake after an incubation time of 1?h varied widely with different cell lines (2-8?pmol/106 cells) and did not correlate with growth inhibitory concentrations (IC50 values), which also varied widely (1.2-9?nM). Changes in the length of the N-linked side chain of SN 28049 had large effects on drug uptake by Co38P cells. SN 28049 uptake by CCRF/CEM cells was only slightly affected by the expression of P-glycoprotein (CEM/VLB100) or MRP1 protein (CEM/E1000). As measured by cytoplasmic fluorescence, SN 28049 was taken up rapidly and retained strongly by Co38P cells, DACA was taken up rapidly and retained poorly, and doxorubicin was taken up slowly and retained moderately. Conclusions The results suggest that SN 28049 is actively transported into cytoplasmic vesicles. While vesicle-associated drug is not important for intrinsic cytotoxicity, it may play a key role as a “slow release-form that modifies pharmacokinetics in multicellular structures such as tumours.